Cantor Fitzgerald Reiterates “$50.00” Price Target for Aclaris Therapeutics (ACRS)
Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics (NASDAQ:ACRS) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2018 earnings at ($4.64) EPS.
Other research analysts also recently issued research reports about the company. BidaskClub raised Aclaris Therapeutics from a sell rating to a hold rating in a report on Tuesday, December 12th. Leerink Swann reduced their target price on Aclaris Therapeutics from $56.00 to $54.00 and set an outperform rating on the stock in a report on Tuesday, March 13th. Zacks Investment Research downgraded Aclaris Therapeutics from a hold rating to a sell rating in a report on Wednesday, January 3rd. Finally, Guggenheim assumed coverage on Aclaris Therapeutics in a report on Thursday, February 8th. They set a buy rating and a $53.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $43.83.
Aclaris Therapeutics stock opened at $18.01 on Monday. Aclaris Therapeutics has a 1-year low of $17.27 and a 1-year high of $33.10. The company has a market capitalization of $552.52, a P/E ratio of -7.47 and a beta of 1.45.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. increased its position in Aclaris Therapeutics by 27.9% in the 4th quarter. Franklin Resources Inc. now owns 2,596,814 shares of the biotechnology company’s stock valued at $64,037,000 after acquiring an additional 565,945 shares during the period. BlackRock Inc. increased its position in shares of Aclaris Therapeutics by 28.4% during the 4th quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock valued at $54,129,000 after purchasing an additional 485,146 shares during the period. Eagle Asset Management Inc. increased its position in shares of Aclaris Therapeutics by 1.7% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,380,549 shares of the biotechnology company’s stock valued at $36,446,000 after purchasing an additional 22,576 shares during the period. Point72 Asset Management L.P. increased its position in shares of Aclaris Therapeutics by 3.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock valued at $23,030,000 after purchasing an additional 29,896 shares during the period. Finally, Driehaus Capital Management LLC increased its position in shares of Aclaris Therapeutics by 73.8% during the 4th quarter. Driehaus Capital Management LLC now owns 523,428 shares of the biotechnology company’s stock valued at $12,908,000 after purchasing an additional 222,254 shares during the period. Hedge funds and other institutional investors own 92.19% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.